Amrutanjan Health Care Limited (AMRUTANJAN) AI Stock Analysis

• Market Cap: ₹19.64B
• Dividend Yield: 0.7%
• Average Volume (3M): 1.41K
• Price to Earnings (P/E): 35.6
• Beta (1Y): 0.82
• Revenue Growth: 8.20%
• EPS Growth: 28.18%
• Country: IN
• Employees: 634
• Sector: Healthcare
• Sector Strength: 40
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 2.88
• Shares Outstanding: 29,230,630
• 10 Day Avg. Volume: 938
• 30 Day Avg. Volume: 1,413
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹778.00
• Price Target Upside: 15.77% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 70 Outperform
• Price Target: ₹778.00 ▲(15.77% Upside)

Amrutanjan Health Care Limited scores well in financial performance, reflecting strong revenue and profit growth and a robust balance sheet. However, the high P/E ratio suggests potential overvaluation, and technical indicators are mixed, showing short-term weakness. The lack of earnings call and corporate events data does not provide additional insights.

Amrutanjan Health Care Limited Business Overview & Revenue Model

Company Description

Amrutanjan Health Care Limited (AMRUTANJAN) is a prominent Indian company operating in the healthcare sector. Founded in 1893, the company specializes in pain management solutions, offering a wide array of products including pain balms, healthcare products, and personal hygiene items. Amrutanjan is renowned for its flagship product, the Amrutanjan Pain Balm, which has become a household name across India. Besides pain relief, the company has diversified into other segments such as beverages and hygiene, with a focus on expanding its consumer base and product offerings.

How the Company Makes Money

Amrutanjan Health Care Limited generates revenue primarily through the sale of its diverse range of healthcare products. The company's key revenue streams include its pain management solutions, particularly the Amrutanjan Pain Balm, which remains a top contributor to its sales. Additionally, the company has expanded into the beverages segment with products like fruit juices and other refreshing drinks, broadening its market reach and increasing revenue potential. Amrutanjan also capitalizes on its personal hygiene products, which cater to a growing demand for health and wellness solutions. The company benefits from a well-established distribution network and strategic marketing initiatives that enhance brand visibility and consumer engagement, thereby driving sales and profitability.

Amrutanjan Health Care Limited Financial Statement Overview

Summary

Amrutanjan Health Care Limited demonstrates strong financial health with consistent revenue and profit growth, solid balance sheet management, and healthy cash flows. While the company shows strong profitability and liquidity, the variability in certain operational metrics indicates areas for improvement in efficiency and cost control.

Income Statement

Amrutanjan Health Care Limited shows a solid performance with steady revenue growth, increasing from 2020 to 2025. Gross and net profit margins are healthy, indicating strong profitability. However, fluctuations in EBIT and EBITDA margins over the years suggest some cost management challenges.

Balance Sheet

The company maintains a strong balance sheet with a low debt-to-equity ratio, indicating prudent leverage management. Consistent growth in stockholders' equity and a robust equity ratio underpin financial stability. The cash reserves are substantial, enhancing liquidity.

Cash Flow

Cash flow analysis reveals a positive trend in operating cash flow and effective capital expenditure management. However, free cash flow growth has been inconsistent, suggesting potential volatility in cash generation. The company maintains a healthy operating cash flow to net income ratio, indicating efficient cash conversion.

Breakdown	Mar 2025	Mar 2023	Mar 2024	Mar 2021	Mar 2022
Income Statement
Total Revenue	4.69B	3.80B	4.21B	3.32B	4.05B
Gross Profit	2.46B	1.98B	2.09B	1.91B	2.25B
EBITDA	758.79M	590.79M	681.60M	861.66M	946.99M
Net Income	508.35M	398.35M	449.73M	611.90M	671.89M
Balance Sheet
Total Assets	4.21B	3.62B	3.67B	2.74B	3.50B
Cash, Cash Equivalents and Short-Term Investments	831.56M	1.93B	2.10B	1.75B	2.01B
Total Debt	20.78M	9.09M	17.28M	13.42M	8.80M
Total Liabilities	947.73M	713.21M	783.82M	587.06M	847.44M
Stockholders Equity	3.27B	2.91B	2.88B	2.16B	2.65B
Cash Flow
Free Cash Flow	153.46M	102.91M	211.93M	878.02M	287.32M
Operating Cash Flow	508.99M	192.18M	279.11M	897.63M	521.96M
Investing Cash Flow	-309.66M	-24.75M	191.65M	-877.61M	-362.12M
Financing Cash Flow	-134.90M	-140.26M	-482.66M	-63.17M	-167.02M

Amrutanjan Health Care Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 672.05
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:AMRUTANJAN, the sentiment is Neutral. The current price of 672.05 is below the 20-day moving average (MA) of 677.16, below the 50-day MA of 700.88, and below the 200-day MA of 687.48, indicating a neutral trend. The MACD of -9.88 indicates Negative momentum. The RSI at 49.26 is Neutral, neither overbought nor oversold. The STOCH value of 46.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:AMRUTANJAN.

Amrutanjan Health Care Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMRUTANJAN	70 Outperform	₹19.64B	35.61		0.70%	8.20%	28.18%
TTKHLTCARE	67 Neutral	₹16.17B	25.63		0.87%	8.10%	-19.89%
KRSNAA	65 Neutral	₹26.05B	32.35		0.31%	13.78%	32.19%
Sector *	51 Neutral	$7.41B	-0.29	-44.86%	2.30%	23.46%	-0.02%
INDOCO	47 Neutral	₹26.90B	96.22		0.53%	-8.28%	-247.34%
ZOTA	40 Neutral	₹39.26B	―		0.08%	71.72%	-125.44%